Selonsertib fails to meet phase 3 endpoint for NASH-fibrosis reduction

Gilead Sciences announced that the STELLAR-3 phase 3 study of selonsertib for patients with bridging fibrosis due to nonalcoholic steatohepatitis did not meet the prespecified 48-week primary endpoint of 1-stage or more histological improvement in fibrosis without worsening of nonalcoholic steatohepatitis, according to a press release.
“While we had hoped for different outcomes from the STELLAR program, we remain focused and committed to developing highly effective treatments for patients living with advanced fibrosis due to NASH,” John G. McHutchison, AO, MD, chief scientific

Source link

Related posts

Recurrent low-grade dysplasia increases CRC risk in patients with IBD


Top 5 gastroenterology articles posted in December


Associations between calcium and magnesium intake and the risk of incident oesophageal cancer: an analysis of the NIH-AARP Diet and Health Study prospective cohort


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy